Dr. John Mars, MD
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $152,652 | 85 | 99.7% |
| Travel and Lodging | $420.64 | 5 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $117,156 | 69 | $0 (2024) |
| Shire North American Group Inc | $35,917 | 21 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,133 | 18 | Takeda Pharmaceuticals U.S.A., Inc. ($28,133) |
| 2023 | $17,899 | 10 | Takeda Pharmaceuticals U.S.A., Inc. ($17,899) |
| 2022 | $24,728 | 14 | Takeda Pharmaceuticals U.S.A., Inc. ($24,728) |
| 2021 | $23,724 | 14 | Takeda Pharmaceuticals U.S.A., Inc. ($23,724) |
| 2020 | $22,671 | 13 | Takeda Pharmaceuticals U.S.A., Inc. ($22,671) |
| 2019 | $21,996 | 12 | Shire North American Group Inc ($21,996) |
| 2018 | $13,921 | 9 | Shire North American Group Inc ($13,921) |
All Payment Transactions
90 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,193.33 | General |
| 11/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $548.33 | General |
| 11/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $109.36 | General |
| 11/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,193.33 | General |
| 10/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,193.33 | General |
| 09/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $548.33 | General |
| 09/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $53.60 | General |
| 09/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,193.33 | General |
| 08/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,193.33 | General |
| 07/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,193.33 | General |
| 06/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 05/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $1,046.66 | General |
| 05/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $107.20 | General |
| 05/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 04/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 03/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 02/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 01/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 12/15/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 11/10/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 10/09/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 09/25/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $1,046.66 | General |
| 09/25/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | Cash or cash equivalent | $105.46 | General |
| 09/13/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 07/14/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
About Dr. John Mars, MD
Dr. John Mars, MD is a Preventive Medicine/Occupational Environmental Medicine healthcare provider based in Longmont, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1316077506.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Mars, MD has received a total of $153,073 in payments from pharmaceutical and medical device companies, with $28,133 received in 2024. These payments were reported across 90 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($152,652).
Practice Information
- Specialty Preventive Medicine/Occupational Environmental Medicine
- Location Longmont, CO
- Active Since 03/06/2007
- Last Updated 09/28/2018
- Taxonomy Code 2083P0500X
- Entity Type Individual
- NPI Number 1316077506
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.